Mario Castro, MD, MPH

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Mario Castro, MD, MPH sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting early-phase tilt upper half by trial count

Mario Castro, MD, MPH: 1 sponsored US clinical trial, 1 recruiting.

Mario Castro, MD, MPH sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Other Lung Disease, with 1 trials.

Mid-pack sponsor footprint

Mario Castro, MD, MPH is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

What is open in the Mario Castro, MD, MPH pipeline

1 recruiting of 1 indexed (100% open).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: Other Lung Disease (1 trial), 6 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Mario Castro, MD, MPH: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Mario Castro, MD, MPH sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share Mario Castro, MD, MPH1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Mario Castro, MD, MPH sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Mario Castro, MD, MPH sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

What to do with this Mario Castro, MD, MPH page

1 registered trials is a research-attention snapshot, not an endorsement of Mario Castro, MD, MPH or any single study.

  • 1 of Mario Castro, MD, MPH's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Other Lung Disease is the condition Mario Castro, MD, MPH studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Other Lung Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Mario Castro, MD, MPH pipeline card: 1 registered trials from official public datasets.Report a data error.